New combination therapy for chronic kidney disease with high proteinuria
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs (zibotentan and dapagliflozin) compared to dapagliflozin alone in people with chronic kidney disease and high protein in their urine. The goal is to see if the combination works better at protecting your kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have chronic kidney disease with a certain level of kidney function (eGFR between 20 and 90) and high protein in your urine (more than 700 mg/g or 1000 mg/g).
- You must be on a stable dose of a blood pressure medication (ACE inhibitor or ARB) for at least 4 weeks.
- You cannot have moderate to severe heart failure (Class III or IV), Type 1 diabetes, or a recent heart-related hospitalization.
- If you are a woman who can get pregnant, you must use effective birth control and have a negative pregnancy test.
- You must not have other serious medical conditions that would make the study unsafe, like severe liver disease or a history of certain cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining dapagliflozin (a water-pill-like diabetes drug) with finerenone (a kidney-protective medication) works better than dapagliflozin alone for people with type 2 diabetes and kidney damage. Both drugs help reduce protein in urine and may slow kidney disease progression.
This study tests a four-drug combination to see if it can better protect the kidneys in people with type 2 diabetes and kidney disease. If you qualify, you may receive this combination therapy and be monitored for 6 months.
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
This trial tests if adding dapagliflozin to baxdrostat (a new blood pressure drug) reduces protein in urine better than baxdrostat alone in people with chronic kidney disease and high blood pressure. It aims to find a more effective way to protect kidney health.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests a combination of two medications (balcinrenone and dapagliflozin) to help protect your kidneys if you have moderate-to-severe chronic kidney disease. The trial evaluates whether this combination slows kidney damage and improves kidney health.
Hear when a new Chronic Kidney Disease With High Proteinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.